Blood test timing could unlock secrets of advanced breast cancer

NCT ID NCT07681323

Recruiting now Knowledge-focused Sponsor: Geneplus-Beijing Co. Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 23, 2026 · Updated 5 times

Summary

This study looks at how the timing of a blood test that detects tumor DNA (ctDNA) affects understanding of prognosis and treatment choices in people with advanced HR+/HER2- breast cancer. Researchers will follow 400 participants to see how ctDNA levels and gene mutations relate to survival and treatment response. The goal is to learn whether earlier or later testing provides better information for guiding care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors better predict outcomes and tailor treatments for advanced breast cancer patients.
What could go wrong: This is an observational study, so it does not test a new treatment. Results may not change practice without further trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED BREAST CANCER

Contacts and locations

Locations

Cancer Institute and Hospital, Chinese Academy of Medical Sciences
RECRUITING

Beijing, 100100, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.